Anna Ochsner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Ochsner has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Anthony Mega
The Warren Alpert Medical School of Brown University, Providence, RI, USA; Lifespan Cancer Institute, Department of Hematology and Oncology, The Miriam Hospital, The Legorreta Cancer Center, Providence, RI, USA
2 shared publications- Kamil Malshy
Department of Urology, University of Rochester Medical Center, Rochester, NY
2 shared publications Aaron Maxwell
The Warren Alpert Medical School of Brown University, Providence, RI, USA; Division of Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Providence, RI, USA
1 shared publication- Alexander Homer
The Warren Alpert Medical School of Brown University Providence Rhode Island USA
1 shared publication Andrew George
Laboratory of Translational Oncology and Translational Cancer Therapeutics, Warren Alpert Medical School of Brown University, Providence, RI
1 shared publication- Benedito Arruda Carneiro
Legorreta Cancer Center, Brown University, Providence, RI 02912, USA
1 shared publication
Latest Publications
- Open Access
ONC201 in combination with ATR inhibitor ceralasertib exhibits potent synergy in ovarian cancer cells
Ovarian cancer stands out as one of the most lethal gynecological cancers among women in the United States. While patients with ovarian cancer often show positive responses to treatment, it is common for the cancer to reappear and develop resistance to treatment, so it is important to explore and create novel combinations to increase patient survival rates. ATRi’s (Ataxia telangiectasia and Rad3-related inhibitors) and ONC201 monotherapies have shown efficacy in ovarian cancer in preclinical models. We hypothesized that combining ATRi’s with ONC201 would enhance this efficacy. ONC201 induces apoptosis through the TRAIL-pathway following activation of the integrated stress response and inactivation of Akt which is upregulated in ovarian cancer. Six human ovarian cancer cell lines were treated alone and with the novel drug combination of ceralasertib (ATRi) and ONC201. We found an IC50 range of 0.88-20.16 μM for ONC201 and IC50 range of 0.55-54.75 μM for ceralasertib. The combination of ONC201 plus ceralasertib resulted in PARP cleavage consistent with apoptosis along with reduction in Bcl-XL, Xiap and p-Akt expression after 72 hours of treatment. Cytokine profiling showed a decrease in markers of inflammation and tumor progression. Our data provide evidence of synergy from the combination of ATRi ceralasertib and ONC201 against Ovarian cancer cells that merits further investigation including clinical translation.
Open AccessONC201 in combination with ATR inhibitor ceralasertib exhibits potent synergy in ovarian cancer cells
Ovarian cancer stands out as one of the most lethal gynecological cancers among women in the United States. While patients with ovarian cancer often show positive responses to treatment, it is common for the cancer to reappear and develop resistance to treatment, so it is important to explore and create novel combinations to increase patient survival rates. ATRi’s (Ataxia telangiectasia and Rad3-related inhibitors) and ONC201 monotherapies have shown efficacy in ovarian cancer in preclinical models. We hypothesized that combining ATRi’s with ONC201 would enhance this efficacy. ONC201 induces apoptosis through the TRAIL-pathway following activation of the integrated stress response and inactivation of Akt which is upregulated in ovarian cancer. Six human ovarian cancer cell lines were treated alone and with the novel drug combination of ceralasertib (ATRi) and ONC201. We found an IC50 range of 0.88-20.16 μM for ONC201 and IC50 range of 0.55-54.75 μM for ceralasertib. The combination of ONC201 plus ceralasertib resulted in PARP cleavage consistent with apoptosis along with reduction in Bcl-XL, Xiap and p-Akt expression after 72 hours of treatment. Cytokine profiling showed a decrease in markers of inflammation and tumor progression. Our data provide evidence of synergy from the combination of ATRi ceralasertib and ONC201 against Ovarian cancer cells that merits further investigation including clinical translation.
- 28 December 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (2) , 102295
Adrenal Metastasis Ablation in Oligometastatic Renal Cell Carcinoma: A Case Series
- 28 December 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (2) , 102295
Adrenal Metastasis Ablation in Oligometastatic Renal Cell Carcinoma: A Case Series
- 5 December 2023
- Published by Elsevier in Cancer Epidemiology
- Vol. 88, 102492
“Shared decision-making” for prostate cancer screening: Is it a marker of quality preventative healthcare?
- 5 December 2023
- Published by Elsevier in Cancer Epidemiology
- Vol. 88, 102492
“Shared decision-making” for prostate cancer screening: Is it a marker of quality preventative healthcare?